# Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal Cancer

> **NCT01733628** · — · COMPLETED · sponsor: **Spanish Breast Cancer Research Group** · enrollment: 143 (actual)

## Conditions studied

- Metastatic Colorectal Cancer
- Metastatic Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01733628
- **Lead sponsor:** Spanish Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-23
- **Primary completion:** 2017-12-19
- **Final completion:** 2017-12-19
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2019-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01733628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01733628, "Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01733628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*